CN118613266A - 神经变性疾病的进展延缓和防御剂 - Google Patents

神经变性疾病的进展延缓和防御剂 Download PDF

Info

Publication number
CN118613266A
CN118613266A CN202280088555.9A CN202280088555A CN118613266A CN 118613266 A CN118613266 A CN 118613266A CN 202280088555 A CN202280088555 A CN 202280088555A CN 118613266 A CN118613266 A CN 118613266A
Authority
CN
China
Prior art keywords
disease
component
combination
febuxostat
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280088555.9A
Other languages
English (en)
Chinese (zh)
Inventor
关根舞
西野武士
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genjin Life Sciences Co ltd
Guan Genwu
Original Assignee
Genjin Life Sciences Co ltd
Genjin Science And Culture Contract Society
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genjin Life Sciences Co ltd, Genjin Science And Culture Contract Society filed Critical Genjin Life Sciences Co ltd
Publication of CN118613266A publication Critical patent/CN118613266A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280088555.9A 2022-01-13 2022-02-07 神经变性疾病的进展延缓和防御剂 Pending CN118613266A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022003851 2022-01-13
JP2022-003851 2022-01-13
PCT/JP2022/004661 WO2023135827A1 (ja) 2022-01-13 2022-02-07 神経変性疾患の進行遅延及び防御剤

Publications (1)

Publication Number Publication Date
CN118613266A true CN118613266A (zh) 2024-09-06

Family

ID=87278717

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280088555.9A Pending CN118613266A (zh) 2022-01-13 2022-02-07 神经变性疾病的进展延缓和防御剂

Country Status (3)

Country Link
JP (1) JPWO2023135827A1 (cg-RX-API-DMAC7.html)
CN (1) CN118613266A (cg-RX-API-DMAC7.html)
WO (1) WO2023135827A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
US6159942A (en) * 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
CN104055124A (zh) * 2013-07-15 2014-09-24 诚志生命科技有限公司 一种具有可持续抗疲劳功能的组合物
WO2017033963A1 (ja) * 2015-08-26 2017-03-02 株式会社スタージェン 細胞内atp増強剤
JP6867142B2 (ja) * 2016-11-17 2021-04-28 株式会社スタージェン パーキンソン症状改善用医薬
WO2018092911A1 (ja) * 2016-11-21 2018-05-24 株式会社スタージェン 細胞内atp増強剤
JP6966840B2 (ja) * 2017-01-24 2021-11-17 株式会社スタージェン 神経変性疾患の改善用医薬
WO2020149218A1 (ja) * 2019-01-18 2020-07-23 学校法人東京女子医科大学 老化防止剤または寿命延長剤

Also Published As

Publication number Publication date
JPWO2023135827A1 (cg-RX-API-DMAC7.html) 2023-07-20
WO2023135827A1 (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
US11427588B2 (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
RU2394580C2 (ru) Способы лечения митохондриальных нарушений
US8088752B2 (en) Methods for metabolic modulation
US20140212382A1 (en) Purine monophosphate prodrugs for treatment of viral infections
Montaigne et al. Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium
CN101184495B (zh) 用于预防或降低患者中的不良作用的方法、组合物和制剂
US12194043B2 (en) Uridine phosphorylase inhibitors to treat or prevent pulmonary disease
Salvi Protecting the myocardium from ischemic injury: a critical role for α1-adrenoreceptors?
WO2014142290A1 (ja) ピラゾール-アミド化合物およびその医薬用途
CN111655258B (zh) 用于冷冻保存的组合物和其使用方法
CN106659701A (zh) 用于治疗年龄相关性症状和疾病的酮基丁酸酯化合物和组合物
US8618074B2 (en) GPCR enhanced neuroprotection to treat brain injury
KR20050097537A (ko) 당뇨병 치료제
JP2004502640A (ja) 肝繊維症、硬変症および脂肪肝を治療および予防するアデノシンa2a受容体拮抗薬
JP2024015132A (ja) O-環状フィトスフィンゴシン-1-フォスフェートを含むパーキンソン病の予防又は治療用組成物
CN101821227A (zh) 激素敏感性脂酶调节剂及使用方法
KR100804622B1 (ko) 글루코즈 내성에 영향을 미치는 약 조제에 대한 사이클릭에테르의 활용
EP3369419B1 (en) Composition for treating diabetes
WO2023135827A1 (ja) 神経変性疾患の進行遅延及び防御剤
US20220125815A1 (en) Synergistic bioactive compositions for enhancing cellular energy
JP4096122B2 (ja) 心臓線維芽細胞の増殖および心線維症を抑制する方法
CN104211747A (zh) 5’-磷酸-n6-(3-羟基苯基)腺苷的制备及医药用途
US20240226131A1 (en) 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment
JP2009078977A (ja) 心筋の小胞体ストレス抑制剤
RS66376B1 (sr) Lečenje fabri pacijenata koji imaju određene mutacije

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20241212

Address after: Niigata Prefecture, Japan

Applicant after: Guan Genwu

Country or region after: Japan

Applicant after: Genjin Life Sciences Co.,Ltd.

Address before: Japan

Applicant before: Genjin science and culture contract society

Country or region before: Japan

Applicant before: Guan Genwu

Applicant before: Genjin Life Sciences Co.,Ltd.

TA01 Transfer of patent application right